Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay

Carol D. Cheli, Deborah L. Morris, Linda Kish, Joan Goldblatt, Irene Neaman, W. Jeffrey Allard, Kwok K. Yeung, Alan H.B. Wu, Robert Moore, Daniel W. Chan, Herbert A. Fritsche, Morton K. Schwartz, Donald L. Very

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


We conducted a multicenter evaluation of the analytical and clinical features of the automated Bayer Immuno 1(TM) CA 15-3(TM) assay and compared assay performance to two manual tests. Results of the 10-day imprecision study of the Bayer Immuno 1 assay pooled across four evaluation sites and three lots of reagent produced total CV ≤4%. Lot-to-lot reproducibility for 26 different lots of reagents and calibrators manufactured over a 2-year period was demonstrated (CV, 1.1%). Results for the Bayer Immuno 1 assay correlated well with the Biomira TRUQUANT® BR(TM) 27.29 and Centocor® CA 15-3 RIAs (r ≤0.94). The upper limit of the reference interval for the Bayer Immuno 1 assay was 35.9 kilounits/L (35.9 units/mL); values were similar for all methods. Longitudinal monitoring of healthy women yielded assay values with an average CV of 11% and 21% for the Bayer Immuno 1 and Biomira assays, respectively. The Bayer Immuno 1 assay demonstrated the analytical features, intermethod correlation, and long-term performance characteristics that are essential for longitudinal monitoring of breast cancer patients.

Original languageEnglish (US)
Pages (from-to)765-772
Number of pages8
JournalClinical chemistry
Issue number4
StatePublished - 1998

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay'. Together they form a unique fingerprint.

Cite this